Related Experiment Video
Updated: Mar 18, 2026

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
Lipid-based nanosystems for CD44 targeting in cancer treatment: recent significant advances, ongoing challenges and
Thais Leite Nascimento1,2,3, Hervé Hillaireau1,2, Juliette Vergnaud1,2
1Institut Galien Paris-Sud, Faculté de pharmacie, Université Paris-Sud, 5 rue JB Clément, 92296 Châtenay-Malabry Cedex, France.
Abstract:
Extensive experimental evidence demonstrates the important role of hyaluronic acid (HA)-CD44 interaction in cell proliferation and migration, inflammation and tumor growth. Taking advantage of this interaction, the design of HA-modified nanocarriers has been investigated for targeting CD44-overexpressing cells with the purpose of delivering drugs to cancer or inflammatory cells. The effect of such modification on targeting efficacy is influenced by several factors. In this review, we focus on the impact of HA-modification on the characteristics of lipid-based nanoparticles. We try to understand how these modifications influence particle physicochemical properties, interaction with CD44 receptors, intracellular trafficking pathways, toxicity, complement/macrophage activation and pharmacokinetics. Our aim is to provide insight in tailoring particle modification by HA in order to design more efficient CD44-targeting lipid nanocarriers.
Related Concept Videos
Modified-Release Drug Delivery Systems: Site-Targeted
Targeted Cancer Therapies
There are several types of targeted therapies against...
Site-Targeted Drug Delivery Systems: Polymeric Carriers

